Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF to Net Income | 87.5% | 43.0% | 85.6% | (220.8%) | (208.5%) | 162.0% | 204.7% | 153.3% | 116.9% | 81.4% | 48.4% | 69.7% | 90.8% | 99.2% | 90.5% | 47.2% | 79.8% | 84.2% | 54.2% | (9.5%) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is (4.8%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for Alnylam Pharmaceuticals, Inc. have been 13.1% over the past three years, and 30.5% over the past five years.
As of today, Alnylam Pharmaceuticals, Inc.'s FCF to Net Income is (4.8%), which is lower than industry median of 83.9%. It indicates that Alnylam Pharmaceuticals, Inc.'s FCF to Net Income is Bad.